Fred Alger Management’s Denali Therapeutics DNLI Stock Holding History

Fred Alger Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-91,807	Closed	-$1.87M	–	434
2024 Q4	$1.87M	Sell	91,807 -29,509	-24%	-$755K	0.01%	335
2024 Q3	$3.53M	Buy	121,316 +94,302	+349%	+$2.34M	0.02%	280
2024 Q2	$627K	Buy	+27,014	New	+$519K	﹤0.01%	369
2022 Q3	–	Sell	-8,983	Closed	-$264K	–	528
2022 Q2	$264K	Buy	+8,983	New	+$235K	﹤0.01%	421
2021 Q2	–	Sell	-16,634	Closed	-$950K	–	517
2021 Q1	$950K	Sell	16,634 -244	-1%	-$16.3K	﹤0.01%	390
2020 Q4	$1.41M	Buy	+16,878	New	+$1.02M	﹤0.01%	348

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fred Alger Management's DNLI Position: Q1 2025 in Review

Fred Alger Management sold out of Denali Therapeutics (DNLI) in Q1 2025, closing a stake of 91,807 shares — an estimated $1.87M sold.

Fred Alger Management first reported a position in DNLI in Q4 2020 and held it in 6 quarters. The position peaked at $3.53M in Q3 2024. 222 funds tracked by Wall St. Rank hold DNLI as of Q1 2025.

Fred Alger Management reported no remaining Denali Therapeutics position as of Q1 2025 after selling out during the quarter.
Fred Alger Management sold 91,807 Denali Therapeutics shares in Q1 2025, an estimated $1.87M.
Fred Alger Management first reported a position in Denali Therapeutics in Q4 2020 and held it in 6 quarters.
Fred Alger Management's Denali Therapeutics position peaked at $3.53M in Q3 2024.
222 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2025.

Based on Fred Alger Management's 13F filing for Q1 2025, filed 16 May 2025.